Literature DB >> 12019123

Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.

Charles Oo1, Joanne Barrett, Albert Dorr, Baolian Liu, Penelope Ward.   

Abstract

Twelve volunteers completed a two-sequence, three-way crossover study of a single 900-mg aspirin dose and multiple doses of 75 mg of oseltamivir in the absence and presence of 900 mg of aspirin. The plasma and urine results demonstrated no pharmacokinetic interaction between oseltamivir and aspirin.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12019123      PMCID： PMC127254          DOI： 10.1128/AAC.46.6.1993-1995.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.

Authors:  J O Miners
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

3.  The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

Authors:  George Hill; Tomas Cihlar; Charles Oo; Edmund S Ho; Ken Prior; Hugh Wiltshire; Jo Barrett; Baulian Liu; Penny Ward
Journal:  Drug Metab Dispos       Date:  2002-01       Impact factor: 3.922

4.  Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.

Authors:  C Oo; J Barrett; G Hill; J Mann; A Dorr; R Dutkowski; P Ward
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

5.  Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.

Authors:  H Wiltshire; B Wiltshire; A Citron; T Clarke; C Serpe; D Gray; W Herron
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-08-18

Review 6.  Clinical pharmacokinetics of the salicylates.

Authors:  C J Needs; P M Brooks
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

7.  Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling.

Authors:  D Dubovská; V K Piotrovskij; M Gajdos; Z Krivosíková; V Spustová; T Trnovec
Journal:  Methods Find Exp Clin Pharmacol       Date:  1995 Jan-Feb
  7 in total
  9 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.

Authors:  V Jullien; D Hubert; O Launay; G Babany; O Lortholary; I Sermet
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

3.  Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients.

Authors:  Brian E Davies; Pau Aceves Baldó; Sian Lennon-Chrimes; Mike Brewster
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

Review 4.  Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.

Authors:  Brian E Davies
Journal:  J Antimicrob Chemother       Date:  2010-04       Impact factor: 5.790

5.  Combination activity of neuraminidase inhibitor oseltamivir and α-tocopherol in influenza virus A (H3N2) infection in mice.

Authors:  Angel S Galabov; Milka Mileva; Lora Simeonova; Galina Gegova
Journal:  Antivir Chem Chemother       Date:  2016-06-24

Review 6.  Safety and pharmacology of oseltamivir in clinical use.

Authors:  Regina Dutkowski; Bharat Thakrar; Enrico Froehlich; Pia Suter; Charles Oo; Penny Ward
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics.

Authors:  J G Coen van Hasselt; Marilee A Andrew; Mary F Hebert; Joel Tarning; Paolo Vicini; Donald R Mattison
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 8.  Respiratory Viruses: Influenza, RSV, and Adenovirus in Kidney Transplantation.

Authors:  Dana J Hawkinson; Michael G Ison
Journal:  Semin Nephrol       Date:  2016-09       Impact factor: 5.299

Review 9.  Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.

Authors:  James R Smith; Craig R Rayner; Barbara Donner; Martina Wollenhaupt; Klaus Klumpp; Regina Dutkowski
Journal:  Adv Ther       Date:  2011-11-01       Impact factor: 3.845
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.